CJC‑1295 + Ipamorelin is a common peptide blend designed to complement your own growth hormone (GH) system, not replace it. Growth hormone is naturally released in pulses, especially at night, and plays a key role in tissue repair, body composition, energy and healthy aging. 

This blend works on two different “switches” in the brain that control GH release:

CJC‑1295 is a long‑acting analogue of Growth Hormone‑Releasing Hormone (GHRH). It binds to the same receptors that your natural GHRH would, encouraging the pituitary gland to release GH in a steady, rhythmic way.

Ipamorelin is a highly selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) also known as the receptor for the hunger hormone Ghrelin. Think of it as a “clean” growth hormone secretagogue: it triggers additional GH pulses through the ghrelin pathway but, unlike many older GH‑releasing peptides, has minimal impact on cortisol, prolactin or other pituitary hormones. 

When used together, CJC‑1295 sets the overall rhythm and background level of GH, while Ipamorelin adds stronger yet still natural pulses. This dual action can result in more youthful GH signalling without the flat, non‑pulsatile pattern seen with synthetic growth hormone injections. GH  causes the secretion of IGF‑1 in liver and other tissues, improving the ability to synthesize protein. 

People typically choose this peptide duo when they’re looking to support deeper sleep, a more youthful metabolism, faster recovery from training or busy schedules, healthier body composition and graceful, active aging.

CJC1295+IPAMORELIN  is not an FDA‑approved medicine and is not intended to diagnose, treat, cure or prevent any disease. Always follow the advice of your prescribing practitioner.

When used as directed and alongside a healthy lifestyle, clients commonly use CJC‑1295 + Ipamorelin to help support:

Deeper, more restorative sleep

Growth hormone naturally peaks in deep (slow‑wave) sleep. By supporting your own GH rhythm, this blend is often used to promote more refreshing sleep, fewer night‑time awakenings and better “next‑day” energy. 

Faster recovery from training & daily stress

GH and IGF‑1 are central to tissue repair. Clients often use this protocol to help their bodies bounce back more quickly from workouts, physical jobs or simply a demanding lifestyle, so muscles and joints feel more prepared for the next day. 

Lean muscle health to support strength & progression

By encouraging natural GH signalling, the blend may help support lean muscle development, training consistency and strength gains over time – especially when combined with progressive resistance training and adequate protein intake. 

Fat metabolism & body‑composition goals

GH secretagogues are being studied for their effects on fat utilisation and body composition. Many users notice that, alongside good nutrition and activity, it’s easier to shift stubborn fat and maintain a leaner look while protecting muscle. 

Everyday energy, focus & resilience

By working with your natural hormone rhythm rather than overriding it, this protocol is often reported to support steadier daytime energy, mental clarity and an overall sense of physical resilience. 

Skin, hair & healthy‑ageing support

Because GH and IGF‑1 influence collagen, cellular repair and body composition, many clinics use this combination in broader “healthy aging” programs aimed at supporting skin quality, body tone and long‑term vitality. 

*Individual results will vary. Best used as part of a complete plan designed by your healthcare provider.

Presentation

5mL multidose vial 

Total peptide content CJC 1295 2000mcg/mL + IPAMORELIN 2000mcg/mL

Excipients

Sterile diluent (e.g., bacteriostatic saline) and standard compounding excipients as specified by the partner pharmacy (may include buffering agents and preservatives).

Protocol & Standard Dosing

Subcutaneous injection into fatty tissue (e.g., lower abdomen, outer thigh), using an insulin type syringe, as instructed by a healthcare professional.

Standard Dose (Maintenance / Symptom Support)

Injectable (Vial)

< 70 kg: 0.10 mL SC nightly on an empty stomach, 5 days per week (5/7)

> 70 kg: 0.15 mL SC nightly on an empty stomach, 5 days per week (5/7)

Administration Method:

Subcutaneous (SC) injection using an insulin syringe into fatty tissue (e.g., lower abdomen or outer thigh), as instructed by a healthcare professional.

Timing & Frequency:

Inject last thing before bed, at least 2 hours after the last meal, and/or upon waking.

Avoid food for 30 minutes after injection.

Use 5 days on / 2 days off each week (5/7 days).

Increased dosing:

May increase to 0.10 mL twice daily in smaller individuals

Or 0.15 mL twice daily in larger individuals

Only if tolerated and clinically indicated, under prescriber guidance.

Side Effects, Reactions & Medical Contraindications

Contraindications – Use is generally not recommended in:

• Known allergy to CJC‑1295, Ipamorelin or any vial component
• Pregnancy or breastfeeding (insufficient safety data) 
• Active malignancy or history of cancer unless cleared by a specialist, due to GH/IGF‑1’s role in cell growth
• Uncontrolled diabetes, significant cardiovascular disease, severe kidney or liver disease without specialist supervision
• Individuals subject to professional or federation anti‑doping testing (WADA / VADA etc.)

Common Side Effects and Adverse Reactions

Often mild and transient where they occur: 

• Injection‑site redness, itching, swelling or small bruises
• Temporary water retention or puffiness
• Increased hunger (usually mild), vivid dreams or changes in sleep pattern
• Headache, light‑headedness or fatigue, especially during the first weeks

Reactions Requiring Medical Attention

Stop injections and contact a healthcare provider (or emergency services if severe) if experiencing:

• Signs of a serious allergic reaction: widespread rash, hives, facial or tongue swelling, difficulty breathing
• Severe or persistent headache, vision changes, chest pain or shortness of breath
• Marked swelling of ankles/hands, rapid unexplained weight gain, or significant changes in blood pressure
• Any new or worsening symptom that feels serious or concerning

Safety Note: Long‑term data is limited. Use should always be monitored by a qualified clinician, with regular reviews and ongoing medical supervision.  Informed consent is essential.